Objective: Nowadays, most patients with celiac disease are diagnosed in adulthood. However, undetected disease may already have been present in childhood and may have subsequently affected growth. Earlier data on the eventual adult height of patients with celiac disease have been scant and inconsistent. We aimed to assess the final height in a large cohort of symptom-detected and screen-detected patients with celiac disease diagnosed in adulthood.

Patients And Methods: The height of 1084 patients with celiac disease diagnosed in adulthood was determined in five separate birth cohorts between the years 1920 and 1989. Further, the patients were evaluated in three different subgroups depending on whether they were diagnosed on the basis of gastrointestinal or extraintestinal symptoms or by serological screening. The population-based control group included 112 340 patients in equal birth cohorts.

Results: In general, the mean adult height of patients with celiac disease was at the same level as in the population at large. In subgroup analysis, men with intestinal symptoms were shorter than the population controls in the birth cohort 1948-1961, and a similar trend was observed in the older cohorts. In women, the mean height was also reduced in the older birth cohorts, but predominantly among screen-detected patients. In the younger birth cohorts, height was reduced in neither sex compared with the population.

Conclusion: In general, the mean adult height of patients with celiac disease is at the same level as that of the general population. In a subgroup analysis, reduced height was observed in some of the older, but not younger, birth cohorts.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0b013e328355a468DOI Listing

Publication Analysis

Top Keywords

celiac disease
28
patients celiac
24
adult height
16
birth cohorts
16
disease diagnosed
12
height patients
12
height
9
patients
9
symptom-detected screen-detected
8
disease
8

Similar Publications

Background&aims: Celiac disease (CD) and potential CD (pCD) are immune-mediated disorders triggered by the ingestion of gluten. In non-celiac gluten sensitivity (NCGS) neither allergic nor autoimmune mechanisms are involved. Relationships between NCGS and CD need to be further investigated.

View Article and Find Full Text PDF

Physical and psychological symptoms and survey importance in celiac disease.

World J Gastrointest Endosc

December 2024

Celiac Disease Center at Columbia University Medical Center, Columbia University, New York, NY 10032, United States.

Celiac disease is an autoimmune condition that affects approximately 1% of the worldwide community. Originally thought to be confined mostly to the small intestine, resulting in villous atrophy and nutrient malabsorption, it has more recently been implicated in systemic manifestations as well, particularly when undiagnosed or left untreated. Herein, the physical and psychological symptoms of celiac disease are described and explored.

View Article and Find Full Text PDF

Olmesartan-Induced Enteropathy: A Rare Case of Chronic Diarrhea.

Case Rep Med

December 2024

Department of Gastroenterology, Gastrocentro Natal, Natal, Rio Grande do Norte, Brazil.

The case involves a 63-year-old hypertensive man, taking antihypertensive medication (olmesartan) for the previous two years, who sought medical attention due to voluminous diarrhea, with several episodes per day and weight loss of 10 kg. He was submitted to a series of diagnostic procedures without elucidation and empirical treatment with unsuccessful outcome. After hospitalization for clinical stabilization and for presenting with duodenal atrophy, obtained by duodenal biopsy associated with negative markers for celiac disease, the patient was diagnosed with suspected olmesartan-induced enteropathy, showing rapid improvement of diarrhea after the drug was withdrawn, with weight regain in 6 months and normalization of the duodenal histological picture after 10 months.

View Article and Find Full Text PDF

What is the Role of Measuring Urinary Gluten Immunogenic Peptides in Clinical Practice in Patients with Coeliac Disease?

J Gastrointestin Liver Dis

December 2024

Academic Unit of Gastroenterology, Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.

Background And Aims: In coeliac disease, the clinical role of the urinary gluten immunogenic peptide is unclear. It has been suggested it can be a non-invasive marker of villous atrophy. Therefore, we present the largest cross-sectional clinical data in patients with coeliac disease to establish the diagnostic accuracy of the urinary gluten immunogenic peptide in identifying villous atrophy.

View Article and Find Full Text PDF

Viral infections in celiac disease: what should be considered for better management.

Clin Exp Med

December 2024

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Following a gluten-free diet (GFD) is known as the main effective therapy available for celiac disease (CD) patients, which in some cases is not enough to heal all patients presentations completely. Accordingly, emerging researchers have focused on finding novel therapeutic/preventive strategies for this disorder. Moreover, previous studies have shown that celiac patients, especially untreated subjects, are at increased risk of developing viral and bacterial infections, which can become a challenge for the clinician.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!